State-of-the-art R&D facility designed to foster collaboration
across world-class science ecosystem
Sustainable environmental engineering aligned to Company’s zero carbon future
AstraZeneca will moment, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre ( Slice) in Cambridge, UK – a state-of-the- art exploration and development ( R&D) installation designed to the world’s loftiest environmental norms and accommodating over exploration scientists.
The new£ 1bn installation will include the most advanced robotics, high- outturn webbing and AI- driven technology. It’ll support AstraZeneca’s focus on specialised and perfection drugs and foster the discovery and development of coming generation rectifiers, including nucleotide- grounded, gene-editing and cell curatives.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said “ Our ambition moment is to not only unveil a structure, but to also drive the coming surge of scientific invention. Our new Discovery Centre in Cambridge raises the bar for sustainable R&D and global collaboration across our assiduity. It’ll allow us to break new boundaries in the understanding of complaint biology, bring life- changing drugs to cases and power the coming stage of our company’s growth.”
The Slice will add to AstraZeneca’s R&D presence in further than 40 countries across the globe, including its other strategic exploration centres in Sweden and the US, and development installations in China and Japan.
The Company invests further than$ 7bn in R&D encyclopedically each time, a large part of which takes place in the UK. The Centre will help farther nurture hookups, develop the coming generation of wisdom leaders and accelerate AstraZeneca’s assiduity- leading situations of productivity.
Located within the Cambridge Biomedical Campus1, the physical propinquity of the structure’s m2 laboratories to leading hospitals, the University of Cambridge, other exploration institutions and a number of biotech companies will promote a culture of open cooperation and invention in its inviting open spaces. The Company has over 200 active collaborations in the region and further than around the world across academia, biotech and assiduity.
During the unveiling moment, His Royal Highness will meet the Chief Executive, the Chairman, Leif Johansson, and other elderly leaders, to shoulder a walking stint of the new installation and make a short address to invited guests.
The Slice and sustainability
Beyond the structure’s expansive scientific capabilities, the slice-suchlike structure is a feat of environmental engineering equipped with 174 boreholes to give natural geothermal energy; four‘ cold-blooded cooling halls’and a ground source heat pump that will save enough energy to power homes.
Low- energy ventilation and high situations of sequestration also help insure the effectiveness of the structure, along with the‘ aphorism-tooth’ roof design which minimises energy use by submerging the innards with natural daylight. This energy effectiveness is aligned to the Company’s Ambition Zero Carbon programme that commits to zero carbon emigrations from its operations across the world by 2025, and for its entire value chain to be carbon negative by 2030.
The life lores cluster in Cambridge
The life lores cluster in Cambridge is the most productive in Europe. It includes further than 400 companies, employing around people and contributing nearly£ 3bn annually to the UK economy2. The megacity has further than doubled its development growth rate over the once five times in life lores and has further patent operations than anywhere differently in the UK
Within close propinquity to AstraZeneca’s new centre is the University of Cambridge’s School of Clinical Medicine, the Medical Research Council Laboratory of Molecular Biology, Cancer Research UK and the Royal Papworth and Addenbrooke’s Hospitals, among others.
Over the once century, roughly 50 Nobel Prize winners in chemistry and physiology or drug have been associated with Cambridge. Important discoveries have included Francis Crick and James Watson’s DNA advance in 1953, and Professor Sir John Gurdon’s work on stem cells in 2012.
AstraZeneca’s global R&D footmark and productivity
The Company has three strategic R&D centres including The Slice in Cambridge, Gaithersburg, Maryland in the lesser Washington,D.C. region in the US, and Gothenburg in Sweden. It has integrated R&D brigades and accelerated decision- making processes, using its unique scientific capabilities, to deliver one of the most productive channels in the assiduity.
Since 2005, AstraZeneca has achieved an nearlysix-fold enhancement in the proportion of its channel motes that have advanced from preclinical disquisition to completion of Phase III clinical trials – from 4 to 23. This enhancement moves AstraZeneca well above the current assiduity average success rate of 14 in the 2018-2020 timeframe.4
Of the Company’s workers, further than work simply in R&D. In 2020, its scientists published a aggregate of calligraphies, with 138 in high impact peer- review journals ( impact factor ³ 15 according to Reuters five- time standing), compared to one in 2010.
AstraZeneca (LSE/ STO/ Nasdaq AZN) is a global, wisdom- led biopharmaceutical company that focuses on the discovery, development, and commercialisation of tradition drugs in Oncology, Rare Conditions, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Grounded in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative drugs are used by millions of cases worldwide.
Source link: https://www.astrazeneca.com/